Jeroen C J Eikenboom

List of Publications by Year in Descending Order

229 papers	8,977 citations	50 h-index	89 g-index
242 ext. papers	10,377 ext. citations	7.5 avg, IF	5.89 L-index

#	Paper	IF	Citations
229	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).. *TH Open*, **2022**, 6, e60-e69	2.7	
228	Measuring anxiety and depression in young adult men with haemophilia using PROMIS.. *Haemophilia*, **2022**,	3.3	0
227	Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype. *HemaSphere*, **2022**, 6, e718	0.3	0
226	Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a cross-sectional study. *British Journal of Haematology*, **2021**,	4.5	2
225	Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. *Acta Obstetricia Et Gynecologica Scandinavica*, **2021**, 101, 145	3.8	1
224	von Willebrand disease: proposing definitions for future research. *Blood Advances*, **2021**, 5, 565-569	7.8	4
223	Hepatitis C virus in hemophilia: Health-related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12616	5.1	1
222	Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry. *Journal of Thrombosis and Haemostasis*, **2021**, 20, 145	15.4	
221	Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. *Blood Advances*, **2021**, 5, 1513-1522	7.8	0
220	Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity. *Lupus*, **2021**, 30, 1124-1132	2.6	6
219	Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. *Lupus Science and Medicine*, **2021**, 8,	4.6	1
218	Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction. *Haemophilia*, **2021**, 27, 581-590	3.3	2
217	Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice. *Journal of Thrombosis and Thrombolysis*, **2021**, 52, 715-719	5.1	
216	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. *Haemophilia*, **2021**, 27, 876-885	3.3	1
215	Clinical value of early viscoelastometric point-of-care testing during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. *Acta Obstetricia Et Gynecologica Scandinavica*, **2021**, 100, 1656-1664	3.8	5
214	Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. *American Journal of Hematology*, **2021**, 96, 51-59	7.1	6
213	Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors. *Thrombosis Research*, **2021**, 197, 172-178	8.2	6

212	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 645-653	15.4	16
211	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. *HemaSphere*, **2021**, 5, e542	0.3	0
210	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2394-2406	15.4	3
209	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. *Blood Advances*, **2021**, 5, 2987-3001	7.8	0
208	Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2687-2701	15.4	7
207	Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. *Blood Reviews*, **2021**, 49, 100826	11.1	3
206	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. *Blood Advances*, **2021**, 5, 5023-5031	7.8	0
205	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. *Blood Advances*, **2021**, 5, 280-300	7.8	72
204	ADAMTS-13 and bleeding phenotype in von Willebrand disease. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 1331-1339	5.1	1
203	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2145-2154	15.4	9
202	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. *Thrombosis and Haemostasis*, **2020**, 120, 1056-1065	7	2
201	Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?. *Thrombosis Research*, **2020**, 193, 86-89	8.2	97
200	Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. *American Journal of Hematology*, **2020**, 95, 1142	7.1	3
199	Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices. *Expert Review of Cardiovascular Therapy*, **2020**, 18, 363-372	2.5	6
198	Lowering the increased intracellular pH of human-induced pluripotent stem cell-derived endothelial cells induces formation of mature Weibel-Palade bodies. *Stem Cells Translational Medicine*, **2020**, 9, 758-772	6.9	6
197	Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice. *TH Open*, **2020**, 4, e119-e126	2.7	2
196	Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms. *Blood Advances*, **2020**, 4, 2979-2990	7.8	2
195	Congenital platelet disorders and health status-related quality of life. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 100-105	5.1	3

194	AB0430 MORTALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROPSYCHIATRIC SYMPTOMS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1514.2-1514	2.4	
193	AB0383 EXTREME FATIGUE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROPSYCHIATRIC SYMPTOMS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1491.2-1492	2.4	
192	The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects. *American Journal of Hematology*, **2020**, 95, E26-E28	7.1	3
191	Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. *Blood Reviews*, **2020**, 39, 100633	11.1	15
190	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P /Humate P treatment in von Willebrand disease patients. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 295-305	15.4	4
189	Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 706-713	15.4	10
188	The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study. *British Journal of Haematology*, **2020**, 189, 171-181	4.5	3
187	An international survey to inform priorities for new guidelines on von Willebrand disease. *Haemophilia*, **2020**, 26, 106-116	3.3	20
186	More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism. *Thrombosis Research*, **2020**, 196, 435-436	8.2	8
185	Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2721-2731	15.4	3
184	Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. *Lupus*, **2020**, 29, 1892-1901	2.6	5
183	Illness cognitions associated with health-related quality of life in young adult men with haemophilia. *Haemophilia*, **2020**, 26, 793-799	3.3	
182	Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA. *Thrombosis and Haemostasis*, **2020**, 120, 1569-1579	7	5
181	Incidence and Clinical Significance of Cerebral Embolism During Atrial Fibrillation Ablation With Duty-Cycled Phased-Radiofrequency Versus Cooled-Radiofrequency: A Randomized Controlled Trial. *JACC: Clinical Electrophysiology*, **2019**, 5, 318-326	4.6	7
180	Predictive value of a bleeding score for postpartum hemorrhage. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 277-284	5.1	3
179	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. *American Journal of Hematology*, **2019**, 94, E201-E205	7.1	7
178	Standardization of methods to quantify and culture endothelial colony-forming cells derived from peripheral blood: Position paper from the International Society on Thrombosis and Haemostasis SSC. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1190-1194	15.4	21
177	Professional functioning of young adults with congenital coagulation disorders in the Netherlands. *Haemophilia*, **2019**, 25, e138-e145	3.3	3

176	Comparison of thromboelastometry by ROTEM Delta and ROTEM Sigma in women with postpartum haemorrhage. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2019**, 79, 32-38	2	21
175	Variability of von Willebrand factor-related parameters in endothelial colony forming cells. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1544-1554	15.4	6
174	Von Willebrand Disease: From In Vivo to In Vitro Disease Models. *HemaSphere*, **2019**, 3, e297	0.3	1
173	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. *Blood Advances*, **2019**, 3, 4147-4154	7.8	6
172	Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage. *JAMA Network Open*, **2019**, 2, e1915628	10.4	8
171	Home treatment of patients with cancer-associated venous thromboembolism - An evaluation of daily practice. *Thrombosis Research*, **2019**, 184, 122-128	8.2	6
170	The prevalence and burden of hand and wrist bleeds in von Willebrand disease. *Haemophilia*, **2019**, 25, e35-e38	3.3	4
169	Sports participation and physical activity in patients with von Willebrand disease. *Haemophilia*, **2019** , 25, 101-108	3.3	7
168	Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort. *Lupus*, **2019**, 28, 94-103	2.6	11
167	Analysis of current perioperative management with Haemate P/Humate P in von Willebrand disease: Identifying the need for personalized treatment. *Haemophilia*, **2018**, 24, 460-470	3.3	19
166	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. *Thrombosis and Haemostasis*, **2018**, 118, 152-160	7	9
165	Health-related quality of life, developmental milestones, and self-esteem in young adults with bleeding disorders. *Quality of Life Research*, **2018**, 27, 159-171	3.7	12
164	Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1357-1368	15.4	11
163	P833Comparison of the pro-coagulant state during ablation using the PVAC Gold and the Thermocool Catheter: results from the CE-AF trial. *Europace*, **2018**, 20, i154-i154	3.9	
162	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. *Thrombosis and Haemostasis*, **2018**, 118, 1690-1700	7	6
161	An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. *Rheumatology*, **2018**, 57, 1707-1720	3.9	17
160	Clinically relevant differences between assays for von Willebrand factor activity. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 2413-2424	15.4	18
159	Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: a nationwide retrospective cohort study. *BMC Pregnancy and Childbirth*, **2018**, 18, 398	3.2	12

158	Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. *Blood Advances*, **2018**, 2, 2433-2442	7.8	20
157	The common single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. *Blood Advances*, **2018**, 2, 1585-1594	7.8	12
156	Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. *British Journal of Haematology*, **2018**, 182, 93-105	4.5	27
155	Von Willebrand's Disease. *New England Journal of Medicine*, **2017**, 376, 701-2	59.2	23
154	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. *Haematologica*, **2017**, 102, 1486-1493	6.6	14
153	Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography. *Vox Sanguinis*, **2017**, 112, 549-556	3.1	11
152	Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. *Rheumatology*, **2017**, 56, 1676-1683	3.9	30
151	Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease. *Haemophilia*, **2017**, 23, 437-443	3.3	5
150	Von Willebrand disease mutation spectrum and associated mutation mechanisms. *Thrombosis Research*, **2017**, 159, 65-75	8.2	30
149	The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. *PLoS ONE*, **2017**, 12, e0187555	3.7	17
148	Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. *Stroke*, **2017**, 48, 3301-3307	6.7	8
147	Joint assessment in von Willebrand disease. Validation of the Haemophilia Joint Health score and Haemophilia Activities List. *Thrombosis and Haemostasis*, **2017**, 117, 1465-1470	7	7
146	P807Asymptomatic cerebral embolism in ablation with the second generation PVAC Gold. *European Heart Journal*, **2017**, 38,	9.5	1
145	Lifecycle of Weibel-Palade bodies. *Hamostaseologie*, **2017**, 37, 13-24	1.9	10
144	Von Willebrand's Disease. *New England Journal of Medicine*, **2016**, 375, 2067-2080	59.2	240
143	Joint surgery in von Willebrand disease: a multicentre cross-sectional study. *Haemophilia*, **2016**, 22, 256-262	3.5	2
142	Hemostatic alterations during coronary artery bypass grafting. *Thrombosis Research*, **2016**, 140, 140-146	8.2	15
141	Developments in the diagnostic procedures for von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 449-60	15.4	40

140	Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. *Chest*, **2016**, 149, 1245-51	5.3	25
139	No Association Between Normalization of VWF Levels and Bleeding Phenotype in Patients with Type 1 VWD - from the Win Study. *Blood*, **2016**, 128, 2577-2577	2.2	3
138	Higher Tinzaparin Dosing Is Needed to Achieve Target Anti-Xa Levels in Pediatric Cardiac Intensive Care Patients. *Pediatric Critical Care Medicine*, **2016**, 17, 203-9	3	7
137	State of the art: von Willebrand disease. *Haemophilia*, **2016**, 22 Suppl 5, 54-9	3.3	16
136	Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial. *Hypertension*, **2015**, 65, 743-50	8.5	46
135	Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. *Journal of Thrombosis and Thrombolysis*, **2015**, 40, 323-30	5.1	4
134	No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 592-600	15.4	15
133	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. *Haemophilia*, **2015**, 21, e185-92	3.3	27
132	Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?. *European Journal of Cardio-thoracic Surgery*, **2015**, 48, e64-70	3	7
131	CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 956-66	15.4	38
130	First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. *British Journal of Haematology*, **2015**, 171, 424-7	4.5	9
129	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. *Haematologica*, **2015**, 100, 188-93	6.6	14
128	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. *Blood*, **2015**, 125, 3006-13	2.2	49
127	Content delivery to newly forming Weibel-Palade bodies is facilitated by multiple connections with the Golgi apparatus. *Blood*, **2015**, 125, 3509-16	2.2	13
126	Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. *Haemophilia*, **2015**, 21, 505-12	3.3	61
125	Angiogenic characteristics of blood outgrowth endothelial cells from patients with von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1854-66	15.4	23
124	Towards the imaging of Weibel-Palade body biogenesis by serial block face-scanning electron microscopy. *Journal of Microscopy*, **2015**, 259, 97-104	1.9	7
123	Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1345-50	15.4	93

122	Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. *PLoS ONE*, **2015**, 10, e0143913	3.7	5
121	The effects of pre- and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysis. *Interactive Cardiovascular and Thoracic Surgery*, **2014**, 18, 292-8	1.8	64
120	STXBP1 promotes Weibel-Palade body exocytosis through its interaction with the Rab27A effector Slp4-a. *Blood*, **2014**, 123, 3185-94	2.2	36
119	Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. *Thrombosis and Haemostasis*, **2014**, 112, 1209-18	7	45
118	Correlative light microscopy and electron tomography to study Von Willebrand factor exocytosis from vascular endothelial cells. *Methods in Cell Biology*, **2014**, 124, 71-92	1.8	5
117	von Willebrand disease and aging: an evolving phenotype. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1066-75	15.4	68
116	Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 regulates epinephrine-induced exocytosis of Weibel-Palade bodies. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 273-81	15.4	14
115	Storage and secretion of naturally occurring von Willebrand factor A domain variants. *British Journal of Haematology*, **2014**, 167, 529-40	4.5	7
114	Recurrence Risk after Limited Duration of Anticoagulant Treatment for Late Second Venous Thromboembolism. *Blood*, **2014**, 124, 591-591	2.2	
113	Genome-wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: Genetics In Familial Thrombosis study. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 1474-84	15.4	18
112	Weibel-Palade bodies: a window to von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 581-92	15.4	36
111	Principles of care for the diagnosis and treatment of von Willebrand disease. *Haematologica*, **2013**, 98, 667-74	6.6	139
110	Reduced prevalence of arterial thrombosis in von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 845-54	15.4	65
109	von Willebrand factor remodeling during exocytosis from vascular endothelial cells. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2009-19	15.4	26
108	Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease. *Blood*, **2013**, 121, 2762-72	2.2	51
107	VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. *Blood*, **2013**, 121, 2336-9	2.2	69
106	von Willebrand disease biology. *Haemophilia*, **2012**, 18 Suppl 4, 141-7	3.3	4
105	Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. *Journal of Proteome Research*, **2012**, 11, 2925-36	5.6	62

104	Formation of platelet-binding von Willebrand factor strings on non-endothelial cells. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 2168-78	15.4	10
103	Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. *Thrombosis and Haemostasis*, **2012**, 108, 683-92	7	64
102	The use of rituximab therapy in patients with acquired factor V inhibitors. *American Journal of Hematology*, **2012**, 87, 826-7	7.1	2
101	Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease. *Haemophilia*, **2012**, 18, 444-51	3.3	9
100	Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation. *Haematologica*, **2012**, 97, 859-66	6.6	27
99	Biogenesis and Exocytosis of Weibel-Palade Bodies Is Affected by Naturally Occurring Von Willebrand Disease Variants within the A1-A3 Domains of VWF. *Blood*, **2012**, 120, 1072-1072	2.2	
98	A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. *Thrombosis Research*, **2011**, 128, 21-6	8.2	53
97	Is a V/Q scan based algorithm correctly used to diagnose acute pulmonary embolism? A daily practice survey. *Thrombosis Research*, **2011**, 128, 221-6	8.2	2
96	Functional architecture of Weibel-Palade bodies. *Blood*, **2011**, 117, 5033-43	2.2	190
95	Factor VIII alters tubular organization and functional properties of von Willebrand factor stored in Weibel-Palade bodies. *Blood*, **2011**, 118, 5947-56	2.2	18
94	A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. *Haemophilia*, **2011**, 17, 165-6	3.3	11
93	Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 603-5	15.4	4
92	Impact of von Willebrand disease on health-related quality of life in a pediatric population. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 502-9	15.4	21
91	Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 1143-8	15.4	89
90	Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316). *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2100-2	15.4	10
89	Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. *Thrombosis and Haemostasis*, **2011**, 106, 885-92	7	49
88	Diagnosis and management of von Willebrand disease in The Netherlands. *Seminars in Thrombosis and Hemostasis*, **2011**, 37, 480-7	5.3	22
87	Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease. *Journal of Biological Chemistry*, **2011**, 286, 24180-8	5.4	34

86	The impact of bleeding history, von Willebrand factor and PFA-100( ) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. *British Journal of Haematology*, **2010**, 151, 245-51	4.5	32
85	Plasma levels of von Willebrand factor, von Willebrand factor propeptide and factor VIII in carriers and patients with nephrogenic diabetes insipidus. *Thrombosis Research*, **2010**, 125, 554-6	8.2	3
84	Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. *Thrombosis Research*, **2010**, 126, 227-31	8.2	21
83	Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. *Thrombosis Research*, **2010**, 126, 345-9	8.2	37
82	Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. *Haematologica*, **2010**, 95, 2163-5	6.6	13
81	Comparison of CT assessed right ventricular size and cardiac biomarkers for predicting short-term clinical outcome in normotensive patients suspected of having acute pulmonary embolism. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 853-6	15.4	34
80	Health-related quality of life among adult patients with moderate and severe von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1492-9	15.4	54
79	Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1547-54	15.4	10
78	von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1986-93	15.4	17
77	Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2078-80	15.4	6
76	The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2377-84	15.4	29
75	Von Willebrand disease and Weibel-Palade bodies. *Hamostaseologie*, **2010**, 30, 150-155	1.9	10
74	Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease. *Blood*, **2010**, 116, 2218-2218	2.2	
73	Von Willebrand disease and Weibel-Palade bodies. *Hamostaseologie*, **2010**, 30, 150-5	1.9	6
72	The value of family history as a risk indicator for venous thrombosis. *Archives of Internal Medicine*, **2009**, 169, 610-5		198
71	Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis. *Transfusion*, **2009**, 49, 570-7	2.9	11
70	Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1304-12	15.4	48
69	The clinical impact of platelet refractoriness: correlation with bleeding and survival. *Transfusion*, **2008**, 48, 1959-65	2.9	73

68	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). *Journal of Thrombosis and Haemostasis*, **2008**, 6, 762-71	15.4	116
67	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): reply to a rebuttal. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 2002-2003	15.4	2
66	Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2008**, 31, 736-41	13.6	64
65	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. *Blood*, **2008**, 111, 3531-9	2.2	162
64	Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). *Blood*, **2008**, 111, 4979-85	2.2	123
63	Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII. *Haematologica*, **2008**, 93, 959-60	6.6	3
62	High D-dimer level is associated with increased 15-d and 3 months mortality through a more central localization of pulmonary emboli and serious comorbidity. *British Journal of Haematology*, **2008**, 140, 218-22	4.5	41
61	ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. *Thrombosis and Haemostasis*, **2007**, 97, 534-541	7	60
60	Acquired von Willebrand syndrome: diagnostic problems and therapeutic options. *American Journal of Hematology*, **2007**, 82, 55-8	7.1	21
59	Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation. *American Journal of Hematology*, **2007**, 82, 376-80	7.1	6
58	Coagulation parameters of thawed fresh-frozen plasma during storage at different temperatures. *Transfusion Medicine*, **2007**, 17, 182-6	1.3	52
57	Haplotypes encoding the factor VIII 1241Glu variation and the risk of myocardial infarction. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 619-21	15.4	5
56	Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). *Journal of Thrombosis and Haemostasis*, **2007**, 5, 715-21	15.4	44
55	High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1562-4	15.4	13
54	Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. *Archives of Internal Medicine*, **2007**, 167, 1593-9		305
53	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). *Blood*, **2007**, 109, 112-21	2.2	309
52	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. *Blood*, **2007**, 109, 2430-7	2.2	57
51	Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. *American Heart Journal*, **2007**, 153, 175-81	4.9	205

50	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. *American Heart Journal*, **2007**, 154, 221-31	4.9	330
49	Plasma coagulation factor levels in venous thrombosis. *Seminars in Hematology*, **2007**, 44, 77-84	4	21
48	Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. *Haematologica*, **2007**, 92, 550-3	6.6	13
47	ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. *Thrombosis and Haemostasis*, **2007**, 97, 534-41	7	23
46	Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. *Thrombosis and Haemostasis*, **2006**, 95, 942-8	7	15
45	Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. *Thrombosis and Haemostasis*, **2006**, 96, 717-24	7	17
44	A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. *Blood*, **2006**, 108, 3210-5	2.2	105
43	Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 774-82	15.4	100
42	A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). *Journal of Thrombosis and Haemostasis*, **2006**, 4, 766-73	15.4	414
41	Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2164-9	15.4	53
40	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2103-14	15.4	884
39	von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2556-62	15.4	79
38	Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease. *British Journal of Haematology*, **2006**, 133, 409-18	4.5	18
37	Efficacy, safety and user-friendliness of two devices for postoperative autologous shed red blood cell re-infusion in elective orthopaedic surgery patients: A randomized pilot study. *Transfusion Medicine*, **2006**, 16, 321-8	1.3	18
36	Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 405-7	15.4	14
35	Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 797-8	15.4	4
34	Cysteine-mutations in von Willebrand factor associated with increased clearance. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2228-37	15.4	66
33	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2619-26	15.4	275

32	Compliance with prophylactic platelet transfusion trigger in haematological patients. *Transfusion Medicine*, **2005**, 15, 45-8	1.3	17
31	Acute myocardial infarction during substitution with recombinant factor VIII concentrate in a patient with mild haemophilia A. *Thrombosis and Haemostasis*, **2004**, 92, 425-426	7	7
30	Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 257-65	15.4	54
29	Immunoglobulin A multiple myeloma presenting with Henoch-Schönlein purpura associated with reduced sialylation of IgA1. *British Journal of Haematology*, **2003**, 122, 915-7	4.5	30
28	The Factor VIII/Von Willebrand Factor Ratio Discriminates between Reduced Synthesis and Increased Clearance of Von Willebrand Factor. *Thrombosis and Haemostasis*, **2002**, 87, 252-257	7	39
27	ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854Gln, and the missense mutation Cys2362Phe. *Blood*, **2002**, 100, 1927-8	2.2	19
26	A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. *Thrombosis Research*, **2002**, 105, 135-8	8.2	12
25	The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. *Thrombosis and Haemostasis*, **2002**, 87, 252-7	7	10
24	Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. *Blood*, **2001**, 98, 2973-9	2.2	70
23	High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. *British Journal of Haematology*, **2001**, 115, 156-8	4.5	69
22	Elevated factor VIII levels and the risk of thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 731-8	9.4	226
21	Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 365-79	4.2	71
20	Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation. *British Journal of Haematology*, **2000**, 108, 188-90	4.5	8
19	Autosomal dominant type 1 von willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. *British Journal of Haematology*, **2000**, 108, 876-9	4.5	34
18	Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. *British Journal of Haematology*, **2000**, 109, 519-22	4.5	61
17	Grossly Abnormal Proteolysis of von Willebrand Factor (VWF) in a Patient Heterozygous for a Gene Deletion and Mutation in the Dimerization Area of VWF. *Thrombosis and Haemostasis*, **2000**, 84, 729-730	7	4
16	Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1382-8	9.4	53
15	Increased Levels of Factor VIII and Fibrinogen in Patients with Venous Thrombosis Are not Caused by Acute Phase Reactions. *Thrombosis and Haemostasis*, **1999**, 81, 680-683	7	187

14	Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation. *Thrombosis and Haemostasis*, **1999**, 82, 1065-1070	7	92
13	Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin. *Thrombosis and Haemostasis*, **1998**, 79, 709-717	7	80
12	Familial Clustering of Factor VIII and von Willebrand Factor Levels. *Thrombosis and Haemostasis*, **1998**, 79, 323-327	7	102
11	Separating short tandem repeat polymorphisms on microgel. *Analytical Biochemistry*, **1997**, 245, 257-9	3.1	
10	The inheritance and molecular genetics of von Willebrand's disease. *Haemophilia*, **1995**, 1, 77-90	3.3	9
9	A novel candidate mutation (Arg611-->His) in type I 'platelet discordant' von Willebrand's disease with desmopressin-induced thrombocytopenia. *British Journal of Haematology*, **1995**, 89, 656-8	4.5	14
8	Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 2221-4	11.5	62
7	Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40. *British Journal of Haematology*, **1993**, 84, 533-5	4.5	16
6	Acquired von Willebrand's disease due to excessive fibrinolysis. *British Journal of Haematology*, **1992**, 81, 618-20	4.5	29
5	A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele. *British Journal of Haematology*, **1992**, 80, 358-63	4.5	42
4	Mutations in Severe, Type III von Willebrand Disease in the Dutch Population: Candidate Missense and Nonsense Mutations Associated with Reduced Levels of von Willebrand Factor Messenger RNA. *Thrombosis and Haemostasis*, **1992**, 68, 448-454	7	39
3	Peri-Operative Replacement Therapy with Factor VII Concentrate in a Patient with Severe Factor VII Deficiency. *Thrombosis and Haemostasis*, **1992**, 67, 285-286	7	6
2	Paroxysmal Finger Haematoma: A Neglected Syndrome. *Thrombosis and Haemostasis*, **1991**, 66, 266-266	7	12
1	Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease148-165		4